ALBANESI, MARCELLO
 Distribuzione geografica
Continente #
NA - Nord America 1.145
EU - Europa 547
AS - Asia 101
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.795
Nazione #
US - Stati Uniti d'America 1.144
DE - Germania 174
IT - Italia 135
SE - Svezia 95
CN - Cina 87
RU - Federazione Russa 59
GB - Regno Unito 54
FR - Francia 10
BE - Belgio 6
IN - India 6
VN - Vietnam 6
PL - Polonia 5
ES - Italia 2
FI - Finlandia 2
IE - Irlanda 2
AZ - Azerbaigian 1
CH - Svizzera 1
DK - Danimarca 1
EU - Europa 1
JP - Giappone 1
NL - Olanda 1
PA - Panama 1
ZA - Sudafrica 1
Totale 1.795
Città #
Fairfield 164
Chandler 154
Houston 118
Ashburn 114
Nyköping 86
Seattle 68
Woodbridge 64
Wilmington 54
Cambridge 47
Ann Arbor 46
New York 37
Beijing 32
Dearborn 22
Lawrence 20
Bari 19
Roxbury 19
Nanjing 14
Des Moines 13
Brooklyn 11
Redwood City 9
San Diego 9
Shenyang 8
Inglewood 7
Brussels 6
Changsha 6
Milan 6
Dong Ket 5
Martina Franca 5
Modugno 5
Paris 4
Pune 4
San Francisco 4
Cutrofiano 3
Edinburgh 3
Jiaxing 3
Jinan 3
Melendugno 3
Nanchang 3
Princeton 3
Turi 3
Washington 3
Barcelona 2
Cerignola 2
Dublin 2
Genoa 2
Grumo Appula 2
Hangzhou 2
Hebei 2
Kunming 2
Norwalk 2
Nuremberg 2
Pomezia 2
Shenzhen 2
Acton 1
Amsterdam 1
Arzano 1
Boardman 1
Bocale 1
Bolzano 1
Brindisi 1
Casamassima 1
Chicago 1
Chiswick 1
Conversano 1
Esslingen am Neckar 1
Fuzhou 1
Gauteng 1
Guangzhou 1
Hefei 1
Helsinki 1
Ho Chi Minh City 1
Hounslow 1
Jacksonville 1
London 1
Lucera 1
Lugano 1
Miami 1
Nardò 1
Niva 1
Nocera Inferiore 1
Palermo 1
Pisa 1
Poggiomarino 1
Reggio Calabria 1
Rogliano 1
Rome 1
San Vendemiano 1
Santeramo In Colle 1
Shanghai 1
Shaoxing 1
Southwark 1
Taizhou 1
Taranto 1
Tokyo 1
Triggiano 1
Warsaw 1
Xian 1
Zhengzhou 1
Totale 1.276
Nome #
Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects 153
Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study 147
Reazioni ritardate a farmaci: dal test di proliferazione linfocitaria alla desensibilizzazione. 135
A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy 103
null 101
Is immunotherapy with fungal vaccines effective? 83
Wasp immunotherapy induced long-term and IgG4-independent protection 82
Test di proliferazione linfocitaria nella diagnosi delle reazioni ritardate a farmaci 78
null 74
Cost-effectiveness of grass pollen allergen immunotherapy in adults 74
Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study 74
null 71
null 68
Studi su Omalizumab nella terapia dell'asma severo. Valutazione degli effetti sulla risposta immunologica IgE in vivo. Valutazione della tollerabilità. 65
Omalizumab in long-term treatment of refractory chronic spontaneus urticaria:effects of discontinuation 64
null 64
Desensitization in Iron Product Allergy 57
null 48
Immunological characterization of onion (Allium cepa) allergy 45
Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2-year real-life study 43
Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: Data from a real-life cohort 39
Desensitization for immediate hypersensitivity to oral dimethyl fumarate (Tecfidera) 35
Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management 29
Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study 29
Delayed allergy to acyclovir revealed by lymphocyte proliferation test 28
A desensitization protocol for delayed allergy to cytarabine: Analysis of two cases 26
Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review 20
Importance of Specific IgE/Total IgE Ratio in Disambiguating Amoxicillin Allergy Diagnosis in a Real-Life Setting 20
Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: A case report 19
Totale 1.874
Categoria #
all - tutte 6.798
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.798


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019120 0 0 0 0 0 0 0 0 0 14 47 59
2019/2020477 42 10 28 47 30 76 43 37 33 46 53 32
2020/2021361 25 52 19 45 43 36 21 38 15 30 13 24
2021/2022181 10 7 6 4 3 21 5 16 8 18 28 55
2022/2023362 28 75 32 20 36 47 7 31 70 2 8 6
2023/2024153 7 22 11 11 9 63 21 8 1 0 0 0
Totale 1.874